MedTrace Logo

Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy

NCT06573411 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2026-04-08

No results posted yet for this study

Summary

This is a prospective, randomized, multicenter, controlled trial. One hundred sixteen patients with primary membranous nephropathy (PMN) will be randomly divided into the intervention and control groups. The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD. Control patients will be administered maximum tolerable dose of ACEI/ARB. The primary endpoint is the relative change in urinary protein content from baseline to 6 months.

Conditions

Interventions

DRUG

ACEI/ARB+ finerenone

The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD.

DRUG

ACEI/ARB

Control patients will be administered maximum tolerable dose of ACEI/ARB.

Sponsors & Collaborators

  • First Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2026-10-30
Completion
2026-10-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06573411 on ClinicalTrials.gov